tada-images-shutterstock

16 November 2023AmericasMarisa Woutersen

Cancer specialist to pay $83.4m over DNA sequencing infringement

TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims